Pathologic Considerations and Standardization in Mesothelioma Clinical Trials

Ming Sound Tsao, Michele Carbone, Francoise Galateau-Salle, Andre L. Moreira, Andrew G. Nicholson, Anja C. Roden, Alex A. Adjei, Marie Christine Aubry, Dean A. Fennell, Daniel Gomez, David Harpole, Mary Hesdorffer, Fred R. Hirsch, Geoffrey Liu, Shakun Malik, Anna Nowak, Tobias Peikert, Ravi Salgia, Peter Szlosarek, Emanuela TaioliHaining Yang, Anne Tsao, Aaron S. Mansfield

Research output: Contribution to journalArticlepeer-review

9 Scopus citations


The accurate diagnosis of mesothelioma is critical for the appropriate clinical management of this cancer. Many issues complicate making the diagnosis of mesothelioma including the presence of reactive mesothelial cells in benign pleural effusions, the heterogeneity of mesothelioma histopathology, the relatively high incidence of other epithelial malignancies that metastasize to the pleura, and primary sarcomas that arise within the pleura. Given the rapidly evolving field of molecular profiling and the need for translational correlates in mesothelioma clinical trials, the National Cancer Institute (NCI)–International Association for the Study of Lung Cancer–Mesothelioma Applied Research Foundation Clinical Trials Planning Meeting was convened in March 2017 to develop a consensus on standard pathology guidelines for future NCI-sponsored clinical trials in mesothelioma. This consensus statement covers recommendations for specimen handling, pathologic classification and diagnosis, biobanking, and tissue correlative studies.

Original languageEnglish
Pages (from-to)1704-1717
Number of pages14
JournalJournal of Thoracic Oncology
Issue number10
StatePublished - Oct 2019


  • Clinical trials
  • Correlatives
  • Mesothelioma
  • Pathologic classification
  • Pathology


Dive into the research topics of 'Pathologic Considerations and Standardization in Mesothelioma Clinical Trials'. Together they form a unique fingerprint.

Cite this